Montana Healthcare Programs
Physician Administered Drug Coverage Criteria

VYEPTI® (eptinezumab-jjmr)

I. Medication Description

Vyepti® is a calcitonin gene-related peptide antagonist indicated for the preventative treatment of migraine in adults.

II. Position Statement

Coverage is determined through a prior authorization process that must include supporting clinical documentation for each request.

III. Initial Coverage Criteria

Member must meet the following criteria:

- 18 years of age or older
- Has a diagnosis of one of the following conditions:
  - Episodic migraines: 4-14 migraine days per month AND <15 headache days per month
  - Chronic migraines: ≥8 migraine days per month AND ≥15 headache days per month
- Must not be concurrently receiving Botox (onabotulinumtoxinA)
- Must have a history of inadequate response (trial of at least two-month duration), contraindication or intolerance to two conventional prophylactic therapies in at least two separate classes below:
  - Amitriptyline or venlafaxine
  - Atenolol, metoprolol, nadolol or propranolol
  - Topiramate or divalproex
- Must have a history of inadequate response (trial of at least three-month duration), contraindication or intolerance to at least one preferred self-administered calcitonin gene-related peptide (CGRP) inhibitors for the same indication
  - List of Montana Healthcare Programs-preferred drugs can be found at https://medicaidprovider.mt.gov/19.
- Vyepti® must not be used concomitantly with other CGRP antagonists.

IV. Renewal Coverage Criteria

Member must meet the following criteria:

- Has been adherent to Vyepti®
- Has experienced a positive clinical response, as demonstrated by a reduction in monthly migraine frequency compared to number of migraine days at baseline

V. Quantity Limitations

Max of 300mg IV every 3 months

VI. Coverage Duration
• Initial approval duration: 6 months
• Renewal approval duration: 1 year